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Summary The p53 gene is contained within 16-20 kb of cellular DNA located on the short arm of human
chromosome 17 at position 17pl3.1. This gene encodes a 393-amino-acid nuclear phosphoprotein involved in
the regulation of cell proliferation. Current evidence suggests that loss of normal p53 function is associated
with cell transformation in vitro and development of neoplasms in vivo. More than 50% of human malignan-
cies of epithelial, mesenchymal, haematopoietic, lymphoid, and central nervous system origin analysed thus
far, were shown to contain an altered p53 gene. The oncoproteins derived from several tumour viruses,
including the SV40 large T antigen, the adenovirus EIB protein and papillomavirus E6 protein, as well as
specific cellular gene products, e.g. murine double minute-2 (MDM2), were found to bind to the wild-type p53
protein and presumably lead to inactivation of this gene product. Therefore, the inactivation of p53 tumour
suppressor gene is currently regarded as an almost universal step in the development of human cancers. The
current data on p53-associated tumourigenesis are briefly discussed in this minireview.
During the past decade, the rapid development of molecular
biology lead to recognition that cancers arise as the result of
accumulation of genetic alterations that interfere with the
normal control of cell growth and differentiation. These
events fall mainly into two distinct categories, i.e., the activa-
tion of proto-oncogenes and inactivation of tumour suppres-
sor genes (Bishop, 1987; Bos, 1989; Fearon & Vogelstein,
1990; Cantley et al., 1991). Proto-oncogenes are normal cel-
lular genes that, when inappropriately activated as
oncogenes, cause dysregulation of growth and differentiation
pathways and enhance the probability of neoplastic transfor-
mation. In contrast to proto-oncogenes, tumour suppressor
genes are normal cellular genes, which when inactivated lead
to a disturbance of cell proliferation and the development of
neoplasias.
Interest was initially focused on oncogenes. The discoveries
of tumour suppressor genes such as the p53 gene, retinoblas-
toma susceptibility gene (RB), the Wilms tumour (WT1)
gene, the deleted in colon carcinoma (DCC) gene, the
mutated in colorectal carcinoma (MCC) gene, the
adenomatous polyposis coli (APC) gene, and the
neurofibromatosis type 1 (NF1) gene, have added a new
dimension to our understanding of human carcinogenesis
(Marshall, 1991; Weinberg, 1991). These genes have quickly
become some of the most intensely studied subjects in cancer
research.
So far, the best known gene of this group is the p53 gene.
This gene is thought to play an important role in the regula-
tion of cell proliferation, and it has been suggested that the
loss of normal p53 function is associated with cell immor-
talisation or transformation in vitro and development of
neoplasms in vivo. The alterations within the coding
sequences of the p53 tumour suppressor gene are among the
most frequent genetic changes detected in human cancers.
The p53 gene or gene product is a common cellular target in
human carcinogenesis provoked by physical factors, chemical
carcinogens or tumour viruses.
The p53 gene and gene product
The p53 gene encompasses 16-20 kb of DNA on the short
arm of human chromosome 17 at position 17pl3.1 (McBride
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et al., 1986; Miller et al., 1986). This gene is composed of
eleven exons, the first of which is noncoding and localised
8-10 kb away from the exons 2-11 (Figure 1). The p53 gene
has been conserved during evolution. In cross-species com-
parison, the p53 proteins show five highly (>90%) con-
served regions among the amino acid residues 13-19,
117-142, 171-181, 234-258, and 270-286 (Figure 1) (Soussi
et al., 1990).
The product of p53 gene is a 393-amino-acid nuclear phos-
phoprotein (about 53 kD in molecular weight). It was first
identified as a cellular protein in 1979 because it formed a
tight complex with the SV40 large T antigen, and therefore
was co-immunoprecipitated with anti-T antibodies from ex-
tracts of SV40-transformed cells (Lane & Crawford, 1979;
Linzer & Levine, 1979). The p53 protein was found in very
low quantities in normal cells, but larger quantities of p53
(5-100-fold) could be detected in transformed cells in culture
and in human tumours.
Function of the p53
The p53 gene was originally regarded as a dominant onco-
gene because its overexpression resulted in immortalisation of
rodent cells, and the p53 gene could transform rat embryo
fibroblasts in concert with an activated ras gene (Jenkins et
al., 1984; Parada et al., 1984; Rovinski & Benchimol, 1988).
It soon became clear, however, that many of these p53 clones
were mutated forms of the gene, and that these mutant alleles
have properties different from those of the wild-type p53
gene (Lane & Benchimol, 1990). When the above experiments
were repeated with the wild-type allele, this allele was found
to suppress or inhibit cell transformation in culture mediated
by either viral or cellular oncogenes (Eliyahu et al., 1989;
Finlay et al., 1989; Hinds et al., 1989). The murine wild-type
p53 gene can suppress the transformation of rat embryo
fibroblasts in cell culture by known oncogenes such as ras
and adenovirus El B (Eliyahu et al., 1989; Finlay et al.,
1989), and the introduction of the wild-type or cDNA into a
transformed cell in culture stops cell growth at the GI phase
of the cell cycle (Baker et al., 1990; Chen et al., 1990; Diller
et al., 1990). More importantly, the wild-type p53 gene is
capable of reverting the transformed phenotype of human
colon (Baker et al., 1990), bladder (Chen et al., 1990), brain
(Mercer et al., 1990) and bone (Diller et al., 1990) cancer cell
lines in vitro.
The molecular mechanisms by which p53 functions nor-
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Figure 1 Schematic diagram of the location and the structure of human p53 gene. Black and stippled rectangles, labelled as
El -ElI, represent exons of human p53 gene. The black regions of the exons code for protein and the stippled regions code for
non-translated proteins of mRNA. The blank rectangles represent introns. Five highly conserved amino-acid sequences among
seven animal species and human beings are illustrated in the black boxes. These regions are the most frequent sites of mutations in
many human turnours. Among these evolutionarily conserved domains, at least four mutation 'hot spots', located at the amino-acid
residues 175, 248, 273 and 282 (indicated as headarrows), have been reported. Abbreviations for the amino-acid residues indicated
in the conserved regions are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N,
Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
mally, and by which it affects tumourigenesis remain unclear.
Documented effects of wild-type p53 on cell proliferation
include regulation of the transition from GI to S-phase of the
cell cycle (Diller et al., 1990; Livingstone et al., 1992; Yin et
al., 1992) and a role in determining cell death through apop-
tosis (Yonish-Rouach et al., 1991). Biological analysis
indicated that p53 plays little part in normal cell cycle cont-
rol, but plays an important growth-controlling role in
stressed cells (Kastan et al., 1992; Lane, 1992). Emerging
evidence also suggests that p53 appears to function normally
as a GI-S checkpoint control for DNA damage (Hartwell,
1992; Kastan et al., 1992; Lane, 1992). Accordingly, normal
p53 may act as a 'molecular policeman' monitoring the integ-
rity of the genome. If DNA is damaged, p53 accumulates
and switches off replication to allow extra time for repair
mechanisms to act. If the repair fails however, p53 may
trigger cell suicide by apoptosis (Lane, 1992).
These regulatory functions may be mediated by the
interaction of p53 protein with specific DNA sequences
(Kern et al., 1991; Hupp et al., 1992; Kern et al., 1992) which
may allow regulation of other genes at the transcriptional
level (Farmer et al., 1992), or perhaps by initiating DNA
replication (Friedman et al., 1990). It has been presumed that
wild-type p53 could regulate the assembly or function of the
DNA replication-initiation complex, or alternatively, p53
could act as a transactivator of gene transcription, either
promoting or inhibiting mRNA synthesis (Levine et al.,
1991). In mutated p53 proteins, the DNA binding capacity,
transcriptional activitor function and initiation of DNA rep-
lication are all altered (Lane & Benchimol, 1990; Friedman et
al., 1990; Farmer et al., 1992; Hupp et al., 1992; Kern et al.,
1992).
Involvement of p53 in tumourigenesis
A substantial amount of evidence has been provided over the
past few years implicating p53 in the development of a wide
range of malignancies..This evidence is derived from at least
five experimental approaches: (1) direct analyses of the p53
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gene reveal that missense mutations or allelic losses occur
frequently in diverse human cancers (Hollstein et al., 1991);
(2) germline mutation of p53 is associated with the Li-
Fraumeni familial cancer syndrome (Frebourg & Friend,
1992); (3) loss of normal p53 function increases susceptibility
of mice to tumour formation (Lavigueur et al., 1989;
Donehower et al., 1992); (4) functional inactivation due to
formation of protein complexes between the wild-type p53
and oncoproteins of several tumour viruses is linked to
tumour virus-mediated oncogenesis (Levine, 1990); and (5)
binding of the wild-type p53 to specific amplified cellular
gene products is associated with the development of certain
human malignancies (Oliner et al., 1992).
Missense mutations and allelic losses ofthe p53 gene
The evolutionarily conserved regions are the most frequent
sites of mutations occurring in many human tumours (Holl-
stein et al., 1991). More than 90% of the substitution muta-
tions reported so far in malignant tumours are clustered
between exon 5 and 8 and are localised in four evolutionarily
conserved regions (i.e., domains II to V in Figure 1). Among
these conserved regions, at least four mutation 'hot spots',
located at the amino-acid residues 175, 248, 273 and 282,
have been identified in a variety of human neoplasms (Figure
1). Mutations in these 'hot spot' codons account for approxi-
mately 30% of all p53 mutations. In most tumours, both p53
alleles are inactivated, one through a point mutation, the
other through a deletion. In addition, most of these p53
mutations in human cancers are missense mutations, giving
rise to an altered protein (Hollstein et al., 1991).
Alterations within the coding sequences of the p53 tumour
suppressor gene are currently regarded as the most frequent
genetic changes in human cancers. Mutations of the p53 gene
are present in all major histogenetic groups. They are found
in epithelial, mesenchymal, haematopoietic and lymphoid
neoplasms as well as in tumours of the central nervous
system (Hollstein et al., 1991; Chang et al., 1993). Approxi-
mately one-half of the adult cancers of the colon (Baker et
al., 1989; Nigro et al., 1989; Shaw et al., 1991) stomach
(Tamura et al., 1991), lung (Nigro et al., 1989; Miller et al.,
1992), esophagus (Hollstein et al., 1991; Bennett et al., 1992),
breast (Nigro et al., 1989; Callahan et al., 1992), liver (Bres-
sac et al., 1991; Hsu et al., 1991; Hsia et al., 1992), brain
(Nigro et al., 1989; Fults et al., 1992), reticuloendothelial
tissues and hematopoietic tissues (Ichikawa et al., 1992;
Sugimoto et al., 1992), analysed so far, contain the mutant
p53 gene. It should be pointed out, however, that the associa-
tion between allelic loss and mutation in cell lines is very
strong but much less work has been done on solid tumours
and it seems that the incidence of p53 mutations in real life is
actually much lower than is seen in vitro (Wright et al., 1991;
Effert et al., 1992). The reported p53 mutations in solid
tumours ranged from a high of 70% (possibly 100%) in lung
cancers to rare occurrences in thyroid and nasopharyngeal
carcinomas (Takahashi et al., 1989; Wright et al., 1991; Effert
et al., 1992). Similarly, in contrast to the reports of a high
percentage of p53 gene alteration and overexpression (Nigro
et al., 1989; Bartek et al., 1991; Callahan et al., 1992; Porter
et al., 1992), Mazars et al. (1992) looked for p53 mutation in
over 90 breast carcinomas and could only find mutations in
some 20% of the lesions. Accordingly, the incidences of p53
mutations vary greatly between tumour types, geographical
locations, as well as from author to author. At present the
reasons for these variations remain unclear. These may stem
from the different experimental approaches used and from
differences in tumour sampling.
Analysis of the reported p53 mutations revealed significant
differences between the tumour types as well as their tissues
of origin. Several consistent features were found in the p53
mutation spectra of human cancers: (1) transitions at CpG
dinucleotide contribute heavily to the mutation frequency in
many cancers. This pattern of mutation may result from
spontaneous mutations arising in mammalian cells (Hollstein
et al., 1991). (2) A mutation at codon 249 predominates in
hepatocellular carcinomas in individuals in the high-incidence
regions. Hepatitis B virus (HBV) infection and aflatoxin
exposure are probably the responsible factors (Bressac et al.,
1991; Hsu et al., 1991; Hsia et al., 1992). (3) Nonclustered G
to T transversions occur frequently in lung, esophageal as
well as head and neck cancers. This may reflect a significant
influence of exogenous carcinogen-exposure, particularly
cigarette smoking and alcohol consumption (Hollstein et al.,
1991; Puisieux et al., 1991). (4) The mutations at dipyrimi-
dine sequences, particularly C to T single base mutations and
less frequent CC to TT double-base transitions have been
significantly associated with ultraviolet radiation and are fre-
quently detected in skin carcinomas. On the other hand, p53
mutational patterns in malignancies of the parenchymal
organs do not show these UV-specific mutations (Brash et
al., 1991; Kress et al., 1992). Therefore, analysis of the p53
mutations may provide clues to the etiology of these diverse
tumours and to the function of specific regions of p53.
Because of its short half-life of about 6-20 min, wild-type
p53 does not normally accumulate in amounts detectable by
conventional immunoprecipitation of immunohistochemical
methods. However, many missense mutations induce changes
which prolong the half-life of the p53 protein up to 6 h
(Levine et al., 1991). Therefore, a detectable protein usually
means mutation, and detection of p53 overexpression by
immunohistochemical techniques is currently used as an
indirect indicator of p53 mutations. More than half of
human malignancies tested so far have been shown to
overexpress the p53 protein (Bartek et al., 1991; Gusterson et
al., 1991; Porter et al., 1992). There are reports of increasing
immunostaining intensity with increasing progression of
neoplasia in surgical samples (Allred et al., 1993; Bell et al.,
1993; Kakeji et al., 1993).
Point mutations in the p53 gene, however, is not the only
mechanism by which the p53 protein can be stabilised. As it
will be discussed later, the normal p53 protein can be
stabilised by the action of viral gene products (SV40 large T
antigen, the adenovirus ElB protein and papillomavirus E6
protein). Furthermore, there is also some evidence to suggest
that p53 stability is affected by cellular proteins, for example,
MDM2. Treatment of cells with DNA-damaging agents such
as UV light, UV mimetic drugs, and -y irradiation has also
been shown to increase the level and stability of the p53
protein (Lu et al., 1992; Hall et al., 1993). Therefore, great
caution should be paid in the interpretation of immunohis-
tochemically positive staining as representing p53 gene muta-
tion (Wynford-Thomas, 1992).
Germline mutation ofp53 and Li-Fraumeni syndrome
The Li-Fraumeni syndrome is a rare familial cancer synd-
rome characterised by diverse mesenchymal and epithelial
neoplasms at multiple sites (Li et al., 1988; Garber et al.,
1991). The spectrum of cancers in this syndrome includes
breast carcinomas, soft tissue sarcomas, brain tumours,
osteosarcoma, leukaemia, adrenocortical carcinoma, and pos-
sibly other tumours. Tumours develop in the family members
at unusually early ages, and multiple primary tumours are
frequent (Li et al., 1988; Garber et al., 1991).
Transmission of the Li-Fraumeni syndrome is autosomal
dominant and the clinical definition requires; (a) an individ-
ual (the proband) with a sarcoma diagnosed before age 45;
(b) a first degree relative with cancer before age 45; and (c)
another first or second degree relative with either a sarcoma
diagnosed at any age or any cancer diagnosed under 45 (Li et
al., 1988; Garber et al., 1991). The relative risk of cancer in
Li-Fraumeni patients during childhood has been estimated to
be 20 (Garber et al., 1991).
Germinal mutations of the p53 gene were first identified in
several families with the Li-Fraumeni syndrome in 1990
(Malkin et al., 1990). Shortly after, a number of case reports
demonstrating the presence of p53 germline mutations were
reported (Srivastava et al., 1990; Law et al., 1991;
Santibanez-Koref et al., 1991). Members of these family con-
tain one mutant p53 allele and one wild-type p53 allele.656 F. CHANG et al.
Furthermore, all the tumour-affected individuals retain the
mutant allele and lose the wild-type p53 allele in their
tumour tissues (Malkin et al., 1990). These phenomena are
consistent with the genetic changes of the RB gene in familial
forms of retinoblastoma, and could well be explained by the
'two hit' hypothesis presented by Knudson (1971). It is
therefore thought that the Li-Fraumeni syndrome patients
are predisposed to cancer because one p53 allele is inac-
tivated in the germline and only the remaining allele needs to
be altered by somatic mutation. In normal individuals
developing a sporadic tumour however, both p53 alleles must
be inactivated in the same cell by somatic mutation.
The first germline mutations described were found in
codons 245 and 258 within one of the evolutionary conserved
domains (Malkin et al., 1990). Later, the analysis of germline
mutations in the Li-Fraumeni syndrome clearly indicated
that they are widely distributed among the p53 gene (Srivas-
tava et al., 1990; Law et al., 1991; Santibanez-Koref et al.,
1991). Most of the germline mutations reported so far are
missense mutations located in the evolutionarily conserved
domains. It should be pointed out that germline mutations
for p53 have not been found in all Li-Fraumeni syndrome-
like families (Santibanez-Koref et al., 1991; Birch, 1992;
Frebourg & Friend, 1992). These negative results must be
analysed with caution. Analysis of the entire p53 gene
sequence in these cases are apparently required. Alterna-
tively, it is possible that germline p53 mutations are not the
only molecular basis of the Li-Fraumeni syndrome. For
example, genetic alterations affecting proteins in the p53
signalling pathway could produce phenotypes identical to the
Li-Fraumeni syndrome (Barnes et al., 1992; Frebourg &
Friend, 1992; Oliner et al., 1992).
The discovery of mutations in the tumour suppressor genes
that occur not only at the somatic level but also in the
germline has important clinical implications. Detection of
such germline mutations should allow identification of sub-
jects at high-risk to develop cancers (Li et al., 1992).
Recently, germline p53 mutations were also found in some
patients who had an unusual history of cancers (e.g., multiple
malignancies and a family history of cancers), but whose
family histories are not fully indicative of the Li-Fraumeni
syndrome (Malkin et al., 1992; Sameshima et al., 1992;
Toguchida et al., 1992). The early detection of such muta-
tions would be useful not only in treating these patients, but
also in identifying family members who may be at high-risk
for the development of tumours.
Tumourformation in transgenic mice
The involvement of p53 in the development of cancers was
also demonstrated in vivo by generating transgenic mice car-
rying mutated p53 genomic fragments (Lavigueur et al., 1989;
Donehower et al., 1992). By microinjection of p53 genomic
fragments derived from either a Friend erythroleukaemia cell
line or BALB/c mouse liver DNA into fertilised eggs of CD-1
mice, Lavigueur et al. (1989) generated a series of transgenic
mice that express the mutant transgene in a wide variety of
tissues. The widespread expression of p53 in these transgenic
animals was associated with a significantly increased
incidence of a broad spectrum of malignancies. Up to 20%
of the transgenic mice developed neoplasms during the
experiment. Although variation in the tumour types derived
from different tissues were observed, lung adenocarcinomas,
osteosarcomas, and lymphomas were particularly preva-
lent.
In the study carried out by Donehower et al. (1992), a null
mutation was introduced into the p53 gene by homozygous
recombination in murine embryonic stem cells. These cells
(carrying a damaged p53 allele) were then injected into blas-
tocysts obtained from normal mice, and the chimeric blasto-
cysts were implanted into pseudopregnant mice. By this way,
they created a unique line of transgenic mice carrying two
non-functional p53 alleles. The mice were developmentally
normal, however, a predisposition towards tumour formation
was again noted at an early age. Nearly 75% (26/35) of the
homozygotes developed a variety of tumours by 6 months (at
ages from 8 to 26 weeks), and 9/26 (35%) mice had multiple
neoplasms. The predominant tumour was malignant lym-
phoma (accounting for >70% of cases). The other tumours
were sarcomas, including haemangiosarcomas, undifferentiated
sarcomas, and osteosarcoma. The incidence of tumours in
the homozygous mice was considerably higher than the 20%
incidence observed by 18 months of age in mice carrying
a mutant p53 transgene, indicating that the presence of a
single wild-type p53 allele was sufficient to reduce tumour
formation.
These results demonstrated that the introduction into the
mouse germ line of abnormal p53 genes results in markedly
elevated tumour susceptibility and provide direct evidence
that p53 plays a causal role in tumour formation. The long
latency period for tumour induction and the overall tumour
incidence, however, suggested that alterations of the p53 gene
alone may not be sufficient for tumour development and that
further genetic or epigenetic changes might be required.
Similar to the observations in human beings, the variety of
tumours identified in the transgenic mice indicate that p53 is
involved in the tumourigenesis of many tissues and cell types.
The experimental results also indicate that the p53 protein
plays an important role in the regulation of cell growth, but
does not have an important function in the mouse develop-
ment and differentiation. This in contrast to the RB tumour
suppressor gene, which has been recently shown to be essen-
tial for normal mouse development (Clarke et al., 1992; Jacks
et al., 1992; Lee et al., 1992).
It was recently noted (Donehower et al., 1992) that fibrob-
lasts derived from the homozygous animals became immor-
talised in tissue culture much more readily than cells from
either the heterozygote or wild-type mice. Thus, the loss of
p53 function is closely correlated with the immortalisation of
cells in tissue culture.
Interaction ofwild-type p53 with oncoprotein of tumour viruses
In addition to the missense mutations that cause inactivation
of p53, an alternative mechanism for inactivation of the
wild-type p53 is to bind to the transforming proteins of DNA
tumour viruses (Levine, 1991). It has been demonstrated that
the SV40 large T antigen (Tan et al., 1986; Schmeig et al.,
1988), the adenovirus E1B protein (Sarnow et al., 1982) and
papillomavirus E6 protein (Scheffner et al., 1990; Werness et
al., 1990) bind to the p53 protein (Figure 2). Similarly, the
SV40 large T antigen (Decaprio et al., 1988), the adenovirus
EIA protein (Whyte et al., 1988) and papillomavirus E7
protein (Dyson et al., 1989; Muinger et al., 1989) bind to the
RB protein (Figure 2). Binding of p53 to SV40 large T or
adenovirus E1B proteins leads to an increased half-life of p53
and presumably inactivates its normal function by formation
of stable complexes. In contrast, E6 proteins from papil-
lomaviruses are known to facilitate the degradation of p53
(Scheffner et al., 1990; Werness et al., 1990).
Accordingly, cancers resulted from tumour virus infections
may contain only wild-type p53 allele. In this regard, cervical
carcinomas could be particularly instructive. Human papil-
lomaviruses (HPVs), especially HPV types 16 and 18, have
been implicated as important etiological factors in the
development of human cervical cancer (Syrjiinen et al., 1987;
Chang, 1990; Howley, 1991; zur Hausen, 1991). More than
90% of cervical carcinomas contain detectable HPV DNA
sequences, many of which constantly express the E6 open
reading frame (Howley, 1991). While the E6 proteins from
HPV 16 and 18 bind to p53, the E6 proteins from HPV types
6 and 11 fail to bind with p53 to a detectable extent
(Scheffner et al., 1990; Werness et al., 1990). This is of
particular interest because HPV 16 and 18 are mostly
associated with invasive carcinomas, and are therefore
regarded as 'high-risk' HPV types, while HPV 6 or 11 are
most frequently found in benign condyloma lesions (Syrjainen
et al., 1987; Chang, 1990; Howley, 1991; zur Hausen, 1991).
Thus, the biological properties of these viruses may be cor-
related with their abilities to associate with the p53. Recently,THE P53 TUMOUR SUPPRESSOR GENE 657
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Figure 2 Schematic diagram of the interaction between tumour virus oncoproteins, p53 and RB. The viral-encoded oncoproteins
of SV40 (large T antigen), type 5 adenovirus (EIA and EIB), and human papillomavirus types 16 and 18 (E6 and E7) are indicated
as rectangles. The black regions of the rectangles represent proposed sites of interaction between the viral oncoproteins and the
tumour suppressor proteins. The known functions of these viral oncoproteins are indicated under the rectangles.
Mietz et al. (1992) demonstrated that the transcritional tran-
sactivation function of wild-type p53 could be inhibited by
the SV40 large T antigen and by the HPV-16 E6 oncop-
rotein. Furthermore, SV40 T antigen mutants that are defec-
tive for p53 binding were not able to inhibit transactivation
and, similarly, HPV E6 proteins that were either mutant or
derived from non-oncogenic HPV types, also had no effect
on p53 transactivation. These results suggested that the
transforming functions of these viral oncoproteins may be
linked to their ability to inhibit p53-mediated transcritional
activation.
Interaction ofwild-type p53 with cellular geneproducts
The p53 pathway may also be disrupted by alteration of a
cellular gene, MDM2 (murine double minute-2). This gene
was originally identified by virtue of its amplification in a
spontaneously transformed mouse cell line (Fakharzadeh et
al., 1991). The mouse MDM2 gene is located in a 'mouse
double minute' chromosome. This gene product was recently
shown to bind to p53 (Momand et al., 1992). By microse-
quencing, Momand et al. (1992) have identified a rat protein
that co-immunoprecipitated with p53 as the rat homologue
of the mouse MDM2 protein. Recently, Oliner et al. (1992)
isolated the human homologue of MDM2, mapped it to the
long arm of human chromosome 12, and showed that it also
can bind to p53. As is the case with the tumour viruses, this
binding appears to inhibit the ability of p53 to transactivate
genes adjacent to p53-binding sites (Momand et al., 1992).
The MDM2 protein was recently found to be able to over-
come the growth-suppressive properties of wild-type p53; and
overexpression of the MDM2 protein resulted in the immor-
talisation and transformation of primary rat embryo fibro-
blasts (Finlay, 1993).
It has been demonstrated that the MDM2 gene is often
amplified in human sarcomas (Oliner et al., 1992). This is
consistent with the previous demonstration of chromosomal
aberrations at this site in these tumours. Therefore, high
numbers of MDM2 gene copies and the consequent overexp-
ression of the MDM2 protein may, like tumour virus oncop-
roteins, inactivate normal p53 functions by complexing to
it.
Mechanisms involved in p53 inactivation
The reasons for tissue-specific mutations of the p53 gene are
unknown. These differences may reflect variable constraints
imposed by the biological characteristics of different tissues
or exposure to different types of carcinogens (Cohen & Ell-
wein, 1991; Harris, 1991; Hollstein et al., 1991; Strauss,
1992). Differences in metabolic and DNA repair capacities in
different tissues and cell types are some of the factors
expected to underline these differences. Typical base changes
in characteristic locations can be related to molecular
mechanisms such as covalent binding of DNA bases by
electrophilic carcinogen metabolites. Endogenous
mechanisms, e.g. DNA polymerase infidelity, depurination,
oxidative damage from free radicals generated by biological
processes, and deamination of 5-methylcytosine can also lead
to mutations (Harris, 1991; Hollstein et al., 1991; Strauss,
1992).
Of the known exogenous carcinogens, many elicit base
substitutions in bacteria, mammalian cells in vitro and in
experimental animals (Harris, 1991; Strauss, 1992). This
activity has been used in short-term tests to identify can-
didate carcinogens. Electrophilic attack of DNA bases by
carcinogen metabolites, followed by fixation of the damage at
the site of the adducted base during DNA replication has
been the principal model of action. Ample biochemical data
exist on the adducts and specific base substitutions expected
from electrophilic metabolites of various important classes of
carcinogens, including N-nitrosamines, polycyclic aromatic
hydrocarbons, and fungal toxins, being consistent with the
results of animal experiments on the specificity of tumour
mutations in ras. The mechanisms of p53 inactivation due to
the formation of protein complexes between viral oncop-
rotein or cellular gene product and wild-type p53 protein,
differ considerably from those elicited by gene alterations.
Tumours resulted from this pathway may contain only wild-658 F. CHANG et al.
type p53. Notable examples include cervical carcinomas
associated with HPV infection, and sarcomas with MDM2
amplification. In both cervical carcinoma (Crook et al., 1991;
Scheffner et al., 1991) and sarcomas with MDM2
amplification (Oliner et al., 1992), p53 mutations appear to
be rare, whereas such mutations are common in other
anogenital malignancies which are not associated with
tumour virus infections, and sarcomas without MDM2
amplification.
A model for p53-associated tumourigenesis
The molecular mechanisms by which the p53 is involved in
tumourigenesis are not fully understood. Based on recent
data, Vogelstein and Kinzler (1992) proposed a model for
p53 gene and gene product function in cell growth control. In
this model, the wild-type p53 gene binds to p53-binding sites
as a tetramer and stimulates the expression of downstream
genes that negatively control cell growth (Stenger et al., 1992;
Vogelstein & Kinzler, 1992). Under normal conditions, the
wild-type p53 appears to play little part in cell cycle control.
However, when cells or cellular DNA are damaged, the cells
increase p53 expression. The accumulation of wild-type p53
switches off the cell cycle until the damage is repaired. If the
repair fails, p53 may further trigger controlled cell death
through apoptosis (Lane, 1992; Vogelstein & Kinzler, 1992).
On the other hand, cells with p53 allelic losses or with
mutant p53 genes are only partially blocked, and therefore
acquire a selective growth advantage (vogelstein & Kinzler,
1992). Clonal expansion of these cells, in combination with
the inactivation of other tumour suppressor genes and/or
activation of certain oncogenes as well as other genetic
changes in the cell, may lead to tumour formation and
progression. Consistent with this hypothesis, recent results
show that loss of wild-type p53 leads to gene amplification at
Physical factors
* radiation
* UV-light
* X-ray
p53 mutation
or allelic loss
high frequency and enhances the possibility of genomic rear-
rangements (Livingstone et al., 1992; Yin et al., 1992). The
enhanced genomic instability may, therefore, accelerate the
occurrence of certain genetic changes that permit cells to
overcome the normal strictures against excessive multiplica-
tion and metastasis and lead to tumour formation and pro-
gression.
As shown in Figure 3, loss of normal p53 function could
be achieved in a variety of ways, including genetic changes in
the p53 gene (e.g., germline mutations, somatic mutation,
small or large deletions, structural rearrangements, and
genomic insertions), formation of protein complexes with
viral oncoproteins (e.g., the SV40 T antigen, adenovirus ElB,
and papillomavirus E6), and binding to the cellular gene
products (e.g., MDM2). Therefore, analysis of the p53 gene
and gene product in tumour cells may reveal significant
differences in its involvement between stages of
tumorigenesis, tumour types as well as their tissues of origin
(Vogelstein & Kinzler, 1992). In some tumours, a loss of one
or both p53 alleles may occur, which reduces the concentra-
tion of p53 tetramers below that required to perform their
normal function. In other tumours, a nonsense mutation
results in the truncation of p53. More commonly, one allele
of p53 develops a missense mutation, and this is accom-
panied by a deletion of the other allele, resulting in the
absence of any wild-type p53 tetramers. This occurs in many
tumours, including those of the colon, brain, lung, liver,
esophagus, and bladder. In cervical cancers, the expression of
HPV E6 results in the functional inactivation of the p53
through binding and degradation. In soft-tissue sarcoma, the
amplification of MDM2 and the binding of its products to
p53 creates a similar loss of functional p53.
These data support the notion that p53 is a common
cellular target in human carcinogenesis mediated by
endogenous factors and exogenous carcinogens as well as
tumour viruses.
Chemical carcinogens
* polycyclic aromatic
hydrocarbons
* nitrosamines
* aflatoxin
* smoking
* alcohol
p53 mutation
or allelic loss
p53 GENE and p53 PROTEIN
germline mutation
mutant p53
Germline mutations
* Li-Fraumeni syndrome
* multiple malignancies
* diverse cancer-prone families
* increased susceptibility to tumour
formation in transgenic mice
neutralisation
wild-type p53
Tumourviruses
* SV40 large T
* adenovirus E1B
* HPV E6
Specific cellular
gene products
* MDM2
Figure 3 Schematic representation of the p53 as a common cellular target in tumorigenesis. Inactivation of the wild-type p53 can
be achieved in a variety of ways, e.g., exposure to physical factors and chemical carcinogens, infections with tumour viruses,
germline mutations, and binding to the specific cellular gene product.THE P53 TUMOUR SUPPRESSOR GENE 659
Conclusions and future prospects
The identification of tumour suppressor genes has broadened
our view of the molecular basis of carcinogenesis. However,
many key issues on the role of p53 gene function and its
association with human carcinogenesis still remain to be
clarified. Further studies are needed to elucidate the role of
p53 in normal and tumour cells. We need to know more
about the frequency of p53 mutations in human tumours.
The investigation of the cell and molecular biology of the p53
in tumours should provide further insights into the regulation
of cell proliferation and its disturbance in tumour cells. With
the advances in our understanding of the process of malig-
nant transformation associated with p53 gene alterations,
some practical applications, e.g., the early detection of
premalignancies and malignancies by molecular diagnosis as
well as the possibility of gene therapy, may emerge.
The original studies of the author (F.C.) has been supported by a
research grant from the Savo Cancer Fund. The excellent help of
Mrs Wang Lijuan in preparation of the manuscript is highly app-
reciated.
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